Screener
Bicara Therapeutics BCAX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other assets | 5,162 | 7,252 |
| Marketable securities | 216,291 | 318,116 |
| Total current assets | 544,915 | 422,053 |
| Property and equipment, net | 346 | 330 |
| Right of use asset – operating lease | 1,428 | 1,701 |
| Other assets | 6,910 | 6,910 |
| Total assets | $553,599 | $430,994 |
| Liabilities and stockholders’ equity |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's PP&E (net)?
- Bicara Therapeutics (BCAX) reported PP&E (net) of $346K in Q1 2026.
- How has Bicara Therapeutics's PP&E (net) changed year-over-year?
- Bicara Therapeutics's PP&E (net) increased by 154.4% year-over-year, from $136K to $346K.
- What is the long-term trend for Bicara Therapeutics's PP&E (net)?
- Over 2 years (2023 to 2025), Bicara Therapeutics's PP&E (net) has grown at a 27.8% compound annual growth rate (CAGR), from $202K to $330K.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Bicara Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude